EquasensFRA:PHF 98 ROA % is 10.04% as of Dec. 2025, which is 20% below its 10-year median of 12.57. GuruFocus rates FRA:PHF with a GF Score™ of 98/100 and a GF Value™ of €85.09. The stock has 2 warning signs investors should review. Among 686 Healthcare Providers & Services companies, Equasens ranks better than 84.4% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Equasens's annualizedNet Income for the quarter that ended in Dec. 2025 was €44.1 Mil.
Equasens's average Total Assets over the quarter that ended in Dec. 2025 was €439.0 Mil. Therefore, Equasens's annualized ROA % for the quarter that ended in Dec. 2025 was 10.04%.
The historical rank and industry rank for Equasens's ROA % or its related term are showing as below:
FRA:PHF'
s ROA % Range Over the Past 10 Years
Min: 9.15 Med: 12.57 Max: 14.98
Current: 9.4
During the past 13 years, Equasens's highest ROA % was 14.98%. The lowest was 9.15%. And the median was 12.57%.
FRA:PHF's ROA % is ranked better than 84.4% of 686
companies
in the Healthcare Providers & Services industry
Industry Median: 1.75
vs FRA:PHF: 9.40
Equasens (FRA:PHF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Equasens ROA % Related Terms
Equasens ROA % Historical Data
* Premium members only.
The historical data trend for Equasens's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Equasens's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equasens ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Equasens's ROA % distribution charts can be found below:
* The bar in red indicates where Equasens's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Equasens (FRA:PHF) has a ROA % of 10.04% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Equasens and its competitors. This is 20% below median its historical median of 12.57. Over the past decade, Equasens' ROA % has ranged from 9.15 to 14.98. According to the industry distribution chart, Equasens ranks #107 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 15.6%.
Is Equasens' ROA % too high?
Equasens' current ROA % of 10.04% is 20% below median its 10-year median of 12.57. Over the past 10 years, this metric has ranged from a low of 9.15 to a high of 14.98. The Healthcare Providers & Services industry median ROA % is 1.75. Equasens' value of 10.04% is 473.7% above this industry median. Based on the distribution chart, Equasens ranks #107 out of 686 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Equasens' ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #107 out of 686 companies for ROA %. This places Equasens in the top 16% of its industry — outperforming the majority of peers. The industry median ROA % is 1.75. Equasens' value of 10.04% is 473.7% above this benchmark. Historically, Equasens' own ROA % has ranged from 9.15 to 14.98 over the past decade. While the company's 10-year median is 12.57 vs. the industry median of 1.75, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current ROA % of 10.04% is 473.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current ROA % is 10.04%, which is 20% below median its own 10-year median of 12.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Equasens (FRA:PHF) has a current ROA % of 10.04%. The stock's GF Value™ is €85.09, compared to a current price of €52.77 — trading 38% below its estimated fair value. The current ROA % is 10.04%, which is 20% below median its 10-year median of 12.57 and 473.7% above the Healthcare Providers & Services industry median of 1.75. Equasens' overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Equasens (FRA:PHF), the current ROA % is 10.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Equasens (FRA:PHF) Overvalued in 2026?
Based on GuruFocus' analysis, Equasens stock appears to be undervalued.
The current stock price of €52.77 is trading 38% below its estimated GF Value™ of €85.09.
Key valuation signals for FRA:PHF:
ROA %: 10.04% (20% below median its 10-year median of 12.57)
GF Value™: €85.09 vs. price of €52.77 (38% below fair value)
Industry Position: 473.7% above the Healthcare Providers & Services median (#107 of 686)
No single metric tells the full story. See the FRA:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
98GF Score
Get the complete analysis for FRA:PHF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHF has been successfully added to your 
